Comparative Clinical and Imaging‐Based Evaluation of Therapeutic Modalities in CNS Embryonal Tumours With PLAGL Amplification
Neuropathology and Applied Neurobiology · 2025
DOI: 10.1111/nan.70015 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Neuropathology and Applied Neurobiology, 2025. Verfasst von Michaela-Kristina Keck und 36 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Glioma Research, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany. Hauptthemen laut MEDLINE: Neoplasms, Germ Cell and Embryonal, Central Nervous System Neoplasms, DNA-Binding Proteins, Brain Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, The Brain Tumour Charity.
Abstract (Originalsprache)
Aims
Embryonal tumours with PLAGL1 or PLAGL2 amplification (ET, PLAGL) show substantial heterogeneity regarding their clinical characteristics and have been treated inconsistently, resulting in diverse outcomes. In this study, we aimed to evaluate the clinical behaviour of ET, PLAGL and elucidate their response pattern across the different applied treatment regimens.
Methods
We conducted an in‐depth retrospective analysis of clinical and serial imaging data of 18 patients with ET, PLAGL (nine each of PLAGL1 and PLAGL2 amplified).
Results
Patients with PLAGL1 ‐amplified tumours (ET, PLAGL1) had fewer relapses (3/9), while PLAGL2 ‐amplified tumours (ET, PLAGL2) were prone to early relapse or progression (8/9) and to distant, leptomeningeal and intraventricular relapses. Progression‐free survival differed significantly between the subtypes (log‐rank test, p = 0.0055). Postoperative treatment included chemotherapy ( n = 17, various protocols), alone ( n = 8) or combined with radiotherapy ( n = 9). Responses to chemotherapy were observed in both subtypes, and incomplete resection was not associated with inferior survival. All three survivors with ET, PLAGL2 were treated with induction and high‐dose chemotherapy with ( n = 1—low‐dose CSI and boost) or without ( n = 2) radiotherapy, whereas five patients with less intensive chemotherapy relapsed. All six survivors with ET, PLAGL1 were treated with conventional chemotherapy regimens, with ( n = 4—local radiotherapy n = 3; CSI and boost n = 1) or without ( n = 2) radiotherapy. Two patients with ET, PLAGL1 relapsed after 8 years.
Conclusions
Adjuvant therapy should be considered for all ET, PLAGL patients: Patients with ET, PLAGL2 might benefit from intensified chemotherapy regimens. In contrast, patients with ET, PLAGL1 showed superior outcomes without high‐dose chemotherapy or craniospinal irradiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Glioma Research, Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
- National Center for Tumor Diseases (NCT), NCT Heidelberg, A Partnership Between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.
- German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Institute of Neuroradiology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Department of Neuroradiology, University Hospital Augsburg, Augsburg, Germany.
- Department of Radiology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
ORCID-Profile: Michaela-Kristina Keck
Förderung
- World Health Organization
- The Brain Tumour Charity
Zitieren
APA
Keck, M. K., Tietze, A., Bison, B., Avula, S., Engelhardt, J., Faure-Conter, C., Fenouil, T., Figarella-Branger, D., Goebell, E., Gojo, J., Haberler, C., Hakumäki, J., Hayden, J. T., Korhonen, L. S., Koscielniak, E., Kramm, C. M., Kranendonk, M. E. G., Lequin, M., Ludlow, L. E., …, & Jones, D. T. W. (2025). Comparative Clinical and Imaging‐Based Evaluation of Therapeutic Modalities in CNS Embryonal Tumours With PLAGL Amplification. Neuropathology and Applied Neurobiology. https://doi.org/10.1111/nan.70015
Vancouver
Keck MK, Tietze A, Bison B, Avula S, Engelhardt J, Faure-Conter C, et al. Comparative Clinical and Imaging‐Based Evaluation of Therapeutic Modalities in CNS Embryonal Tumours With PLAGL Amplification. Neuropathology and Applied Neurobiology. 2025. doi:10.1111/nan.70015
BibTeX
@article{Keck2025,
author = {Keck, Michaela-Kristina and Tietze, Anna and Bison, Brigitte and Avula, Shivaram and Engelhardt, Julien and Faure-Conter, Cécile and Fenouil, Tanguy and Figarella-Branger, Dominique and Goebell, Einar and Gojo, Johannes and Haberler, Christine and Hakumäki, Juhana and Hayden, James T and Korhonen, Laura S and Koscielniak, Ewa and Kramm, Christof M and Kranendonk, Mariëtte E G and Lequin, Maarten and Ludlow, Louise E and Meyronet, David and Nyman, Per and Øra, Ingrid and Perwein, Thomas and Pesola, Jouni and Rauramaa, Tuomas and Reddingius, Roel and Samuel, David and Schouten-van Meeteren, Antoinette Y N and Sexton-Oates, Alexandra and Vasiljevic, Alexandre and von Kalle, Thekla and Wefers, Annika K and Wesseling, Pieter and Zamecnik, Josef and Zapotocky, Michal and von Hoff, Katja and Jones, David T W},
title = {Comparative Clinical and Imaging‐Based Evaluation of Therapeutic Modalities in CNS Embryonal Tumours With PLAGL Amplification},
journal = {Neuropathology and Applied Neurobiology},
year = {2025},
doi = {10.1111/nan.70015}
}
EUVIMED